PPARδ agonist 9

• Description:

  PPARδ agonist 9 (compound 21) is a PPAR�� agonist (EC50: 3.6 nM) . PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) [1].

• UNSPSC:

  12352005

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pparδ-agonist-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC(CC(O)=O)=CC(OCCC2(N3CCCC3)CCN(C4=NC5=CC=C(N=C5S4)C(F)(F)F)CC2)=C1

• Molecular Formula:

  C26H28ClF3N4O3S

• Molecular Weight:

  569.04

• References & Citations:

  [1]Kato T, et al. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4- (1-Pyrrolidinyl) piperidine Structure. J Med Chem. 2023 Aug 24;66 (16) :11428-11446..

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  928023-21-6